Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 2:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 830 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety and Pharmacokinetics in Healthy Volunteer Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3471851 in Healthy Participants

NCT04133116
View directory record Official record
Conditions
Healthy
Interventions
LY3471851, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
20 Years to 64 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 14, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oseltamivir and Its Carboxylate Metabolite, RO0640802 in Healthy Participants

NCT02717754
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Oseltamivir, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Little Rock, Arkansas • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 14, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vitamin E δ-Tocotrienol (VEDT) Single Dose in Healthy Subjects

NCT01446952
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Vitamin E δ-Tocotrienol
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 14, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects

NCT03150108
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
rhPTH(1-84)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 14, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

NCT03207425
View directory record Official record
Conditions
NASH
Interventions
EDP 305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 14, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

NCT00959426
View directory record Official record
Conditions
Obesity, Overweight, Healthy
Interventions
PF-04620110, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 7, 2010 · Synced Oct 14, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606

NCT04041648
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
L606 (Liposomal Treprostinil) Inhalation Solution 51ug, L606 Inhalation System, Placebo Solution
Drug · Device · Other
Lead sponsor
Pharmosa Biopharm Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 14, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3323795 in Healthy Participants

NCT02989389
View directory record Official record
Conditions
Healthy
Interventions
LY3323795, Itraconazole, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 14, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects

NCT00495014
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
GSK376501, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 15, 2010 · Synced Oct 14, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects

NCT01860326
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
Alisporivir
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 14, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus

NCT00882726
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
CNTO 3649 IV (Healthy participants), CNTO 3649 SC (Healthy participants), CNTO 3649 SC (Diabetic patients), Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
Miramar, Florida • San Antonio, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 14, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction

NCT01846468
View directory record Official record
Conditions
Chronic Renal Insufficiency
Interventions
LHW090, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 14, 2026, 2:55 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and Repeat Doses of Supratherapeutic Doses of IV GSK2251052 in Healthy Volunteers

NCT01495065
View directory record Official record
Conditions
Community-acquired Infection
Interventions
GSK2251052 750 mg, GSK2251052 1500 mg, GSK2251052 1500 mg BID, GSK2251052 2250 mg, GSK2251052 3000 mg, GSK2251052 0.9% saline
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 14, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry.

NCT04269031
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD2373 subcutaneous injection, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 14, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011

NCT02431481
View directory record Official record
Conditions
Normal Renal Function, Impaired Renal Function
Interventions
LEE011
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 14, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A PET Study Following a Single Oral Dose of ITI-333 in Healthy Subjects

NCT05470101
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ITI-333
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Creve Coeur, Missouri • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 14, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Multiple Ascending Dose Study for AZD 7268 in Healthy Volunteers

NCT00861718
View directory record Official record
Conditions
Healthy
Interventions
AZD7268, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced Oct 14, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers

NCT00990990
View directory record Official record
Conditions
Tuberculosis
Interventions
PNU-100480, Placebo, Linezolid
Drug
Lead sponsor
Sequella, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 14, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe

NCT06402513
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Ravagalimab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 14, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese Participants

NCT07600762
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Nacresertib, Placebo for Nacresertib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 14, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of TG-0054 With Single IV Doses Escalation in Healthy Volunteers

NCT00822341
View directory record Official record
Conditions
Healthy
Interventions
TG-0054
Drug
Lead sponsor
GPCR Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 14, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of E2609 in Healthy Subjects

NCT01511783
View directory record Official record
Conditions
Healthy
Interventions
E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 14, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers

NCT04273217
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AV-1, Placebo
Drug
Lead sponsor
AbViro LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 14, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy Subjects

NCT01858935
View directory record Official record
Conditions
Healthy
Interventions
ND-L02-s0201 Injection, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 14, 2026, 2:55 AM EDT